Bristol Myers Squibb announced its Opdivo/Yervoy combo therapy for bladder cancer failed in a Phase III study. “Despite some progress in recent years, metastatic urothelial carcinoma remains a difficult disease to address, with a limited number of treatment options that can extend patients’ lives,” said BMS development program lead Dana Walker. (Endpoints News)
Former digital health chief for the Food and Drug Administration, Bakul Patel, is joining Google. Patel will serve as the tech giant’s senior director for global digital health strategy and regulatory affairs, as the company is aiming to get regulatory approvals for its new AI tools. (STAT)
Seagan CEO Clay Siegall resigned following domestic violence allegations. Roger Dansey, the company’s chief medical officer since 2018, will serve as interim CEO until a permanent one is found. (MarketWatch)
The FDA said it will investigate why it took so long for the agency to inspect the Abbott Nutrition baby formula plant. The Michigan facility was shut down in February and the agency is drawing criticism for the nation’s baby formula shortage. (CNBC)
French drugmaker Valneva saw a fifth of its value drop after the European Commission dropped its COVID-19 vaccine agreement. Valneva’s vaccine is based on older technology, such as what has been used for hepatitis and polio vaccines, compared to the mRNA vaccines. (Reuters)
